Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5398_Библиотеки_им_академика_М_И_Перельмана.pdf
Ocular Drug Delivery: Overcoming Barriers for Effective Treatment 279
28. Gote V, Sikder S, Sicotte J et al (2019) Ocular
drug delivery: present innovations and future
challenges. J Pharmacol Exp Ther 370(3):
602–624
29. Nayak K, Misra M (2018) A review on recent
drug delivery systems for posterior segment of
eye. Biomed Pharmacother 107:1564–1582
30. Lane SS, Osher RH, Masket S et al (2008)
Evaluation
cameral moxifoxacin in cataract surgery. J Cataract Refract Surg 34(9):1451–1459
31. Vazirani J, Basu S (2013) Role of topical,
subconjunctival, intracameral, and irrigative
antibiotics in cataract surgery. Curr Opin
Ophthalmol 24(1):60–65
32. Jonas JB, Spandau UH, Schlichtenbrede F
(2008) Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye (Lond) 22(4):590–591
33. Park JG, Callaway NF, Ludwig CA et al
(2020) Intravitreal methotrexate and fuocinolone acetonide implantation for VogtKoyanagiHarada uveitis. Am J Ophthalmol
Case Rep 19:100859
34. Gross A, Cestari DM (2014) Optic neuropathy following retrobulbar injection: a review.
Semin Ophthalmol 29(5–6):434–439
35. Hayashi K, Hayashi H (2005) Intravitreal versus retrobulbar injections of triamcinolone for
macular edema associated with branch retinal
vein occlusion. Am J Ophthalmol 139(6):
972–982
36. Saf M, Ang MJ, Patel P (2020) Rhino-orbitalcerebral mucormycosis (ROCM) and associated cerebritis treated with adjuvant retrobulbar amphotericin B. Am J Ophthalmol
Case Rep 19:100771
37. Inoue K (2014) Managing adverse effects of
glaucoma medications. Clin Ophthalmol 8:
903–913
38. Janoria KG, Gunda S, Boddu SHETAL
(2007) Novel approaches to retinal drug
delivery. Expert Opin Dr ug Deliv 4(4):
371–388
39. Srinivasarao DA, Lohiya G, Katti DS (2019)
Fundamentals, challenges, and
nanomedicine-based solutions for ocular diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 11(4):e1548
40. Peng C, Kuang L, Zhao J et al (2022) Bibliometric and visualized analysis of ocular drug
delivery from 2001 to 2020. J Control
Release 345:625–645
41. Yetisgin AA, Cetinel S, Zuvin M et al (2020)
Therapeutic nanoparticles and their targeted
delivery applications. Molecules 25(9):2193
of the safety of prophylactic intra-
42. Jiang C, Kuang L, Merkel MP et al (2015)
Biodegradable polymeric microsphere-based
drug delivery for inductive browning of fat.
Front Endocrinol (Lausanne) 6:169
43. Ali J, Fazil M, Qumbar M et al (2016) Colloidal dr ug delivery system: amplify the ocular
delivery. Drug Deliv 23(3):710–726
44. Yu A, Shi H, Liu H et al (2020) Mucoadhesive
dexamethasone-glycol chitosan nanoparticles
for ophthalmic drug delivery. Int J Pharm
575:118943
45. Bodoki E, Vostinaru O, Samoila O et al
(2019) Topical nanodelivery system of lutein
for the prevention of selenite-induced cataract. Nanomed Nanotechnol Biol Med
15(1):188–197
46. Abdel-Rashid RS, Helal DA, Omar MM
(2019) Nanogel loaded with surfactant
based nanovesicles for enhanced ocular delivery of acetazolamide. Int J Nanomedicine 14:
2973–2983
47. Pandit J, Sultana Y, Aqil M (2021) Chitosan
coated nanoparticles for efficient delivery of
bevacizumab in the posterior ocular tissues via
subconjunctival administration. Carbohydr
Polym 267(11821):7
48. Kim SN, Min CH, Kim YK et al (2022) Iontophoretic ocular delivery of latanoprostloaded nanoparticles via skin-attached electrodes. Acta Biomater 144:32–41
49. Goyal R, Macri LK, Kaplan HM et al (2016)
Nanoparticles and nanofibers for topical drug
delivery. J Control Release 240:77–92
50. Ahmad I, Pandit J, Sultana Y (2019) Optimization by design of etoposide loaded solid
lipid nanoparticles for ocular delivery: characterization, pharmacokinetic and deposition
study. Mater Sci Eng C Mater Biol Appl 100:
959–970
51. Tatke A, Dudhipala N, Janga KY et al (2018)
In situ gel of triamcinolone acetonide-loaded
solid lipid nanoparticles for improved topical
ocular delivery: tear kinetics and ocular disposition studies. Nanomaterials (Basel) 9(1)
52. Chetoni P, Burgalassi S, Monti D et al (2016)
Solid lipid nanoparticles as promising tool for
intraocular tobramycin delivery: pharmacokinetic studies on rabbits. Eur J Pharm Biopharm 109:214–223
53. Gorantla S, Rapalli VK, Waghule T et al
(2020) Nanocarriers for ocular drug delivery:
current status and translational opportunity.
RSC Adv 10(46):27835 –27855
54. Trivedi
R, Kompella UB (2010) Nanomicellar
formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond) 5(3):485–505
280 Anuradha Nema
55. Liu D, Wu Q, Chen W et al (2019) A novel
FK506 loaded nanomicelles consisting of
amino-terminated poly(ethylene glycol)block-poly(D, L)-lactic acid and hydroxypropyl methylcellulose for ocular drug delivery.
Int J Pharm 562:1–10
56. Terreni E, Chetoni P, Tampucci S et al (2020)
Assembling surfactants-mucoadhesive polymer nanomicelles (ASMP-Nano) for ocular
delivery of cyclosporine-A. Pharmaceutics
12(3)
57. Ghezzi M, Ferraboschi I, Delledonne A et al
(2022) Cyclosporine-loaded micelles for ocular delivery: investigating the penetration
mechanisms. J Control Release 349:744–755
58. Zhao X, Seah I, Xue K et al (2022) Antiangiogenic nanomicelles for the topical delivery of
afibercept to treat retinal neovascular disease.
Adv Mater 34(25):e2108360
59. Singh Y, Meher JG, Raval K et al (2017)
Nanoemulsion: concepts, development and
applications in drug delivery. J Control
Release 252:28–49
60. Akhter S, Anwar M, Siddiqui MA et al (2016)
Improving the topical ocular pharmacokinetics of an immunosuppressant agent with
mucoadhesive nanoemulsions: formulation
development, in-vitro and in-vivo studies.
Colloids Surf B Biointerfaces 148:19–29
61. Lallemand F, Daull P, Benita S et al (2012)
Successfully improving ocular drug delivery
using the cationic nanoemulsion, novasorb. J
Drug Deliv 604204:1
62. Lalu L, Tambe V, Pradhan D et al (2017)
Novel nanosystems for the treatment of ocular infammation: current paradigms and
future research directions. J Control Release
268:19–39
63. Youssef AAA, Cai C, Dudhipala N et al (2021)
Design of topical ocular ciprofoxacin nanoemulsion for the management of bacterial keratitis. Pharmaceuticals (Basel) 14(3):210
64. Ismail A, Nasr M, Sammour O (2020)
Nanoemulsion as a feasible and biocompatible
carrier for ocular delivery of travoprost:
improved pharmacokinetic/pharmacodynamic properties. Int J Pharm 583:119402
65. Zhang J, Jiao J, Niu M et al (2021) Ten years
of knowledge of nano-carrier based drug
delivery systems in ophthalmology: current
evidence, challenges, and future prospective.
Int J Nanomedicine 16:6497–6530
66. Josyula A, Omiadze R, Parikh K et al (2021)
An ion-paired moxifoxacin nanosuspension
eye drop provides improved prevention and
treatment of ocular infection. Bioeng Transl
Med 6(3):e10238
67. Jacob S, Nair AB, Shah J (2020) Emerging
role of nanosuspensions in drug delivery systems. Biomater Res 24:3
68. Wu Y, Vora LK, Mishra D et al (2022)
Nanosuspension-loaded dissolving bilayer
microneedles for hydrophobic drug delivery
to the posterior segment of the eye. Biomater
Adv 137:212767
69. Reimondez-Troitino S, Csaba N, Alonso MJ
et al (2015) Nanotherapies for the treatment
of ocular diseases. Eur J Pharm Biopharm 95
(Pt B):279–293
70. Romero GB, Keck CM, Muller RH et al
(2016) Development of cationic nanocrystals
for ocular delivery. Eur J Pharm Biopharm
107:215–222
71. Tuomela A, Liu P, Puranen J et al (2014)
Brinzolamide nanocrystal formulations for
ophthalmic delivery: reduction of elevated
intraocular pressure in vivo. Int J Pharm
467(1–2):34–41
72. Orasugh JT, Sarkar G, Saha NR et al (2019)
Effect of cellulose nanocrystals on the performance of drug loaded in situ gelling thermoresponsive ophthalmic formulations. Int J
Biol Macromol 124:235–245
73. Abed N, Couvreur P (2014) Nanocarriers for
antibiotics: a promising solution to treat intracellular bacterial infections. Int J Antimicrob
Agents 43(6):485–496
74. Rawas-Qalaji M, Williams CA (2012)
Advances in ocular drug delivery. Curr Eye
Res 37(5):345–356
75. Lajunen T, Nurmi R, Kontturi L et al (2016)
Light activated liposomes: functionality and
prospects in ocular drug delivery. J Control
Release 244(Pt B):157–166
76. Chen X, Wu J, Lin X et al (2022) Tacrolimus
loaded cationic liposomes for dry eye treatment. Front Pharmacol 13:838168
77. Tavakoli S, Peynshaert K, Lajunen T et al
(2020) Ocular barriers to retinal delivery of
intravitreal liposomes: impact of vitreoretinal
interface. J Control Release 328:952–
78. Kale SN, Deore SL (2016) Emulsion micro
emulsion and nano emulsion: a review. Syst
Rev Pharm 8:39–47
79. Mahran A, Ismail S, Allam AA (2021) Development of triamcinolone acetonide-loaded
microemulsion as a prospective ophthalmic
delivery system for treatment of uveitis:
in vitro and in vivo evaluation. Pharmaceutics
13(4):444
80. Kaur IP
Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive
, Aggarwal D, Singh H (2010)
961
Ocular Drug Delivery: Overcoming Barriers for Effective Treatment 281
niosomal delivery system. Graefes Arch Clin
Exp Ophthalmol 248(10):1467–1472
81. Aggarwal D, Pal D, Mitra AK et al (2007)
Study of the extent of ocular absorption of
acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int J Pharm 338(1–2):21–26
82. Zubair
83. Kattar A, Quelle-Regaldie A, Sa´nchez L et al
84. Allam A, Elsabahy M, El Badry M et al (2021)
85. Fathalla D, Fouad EA, Soliman GM (2020)
86. Razavi MS, Ebrahimnejad P, Fatahi Y et al
87. Romeo A, Kazsoki A, Omer S et al (2023)
88. Rohde F, Walther M, Wachter J et al (2022)
89. Tawfk EA, Alshamsan A, Abul Kalam M et al
90. Yaylaci S, Dinc E, Aydın B et al (2023) Pep-
91. Spataro G, Malecaze F, Turrin CO et al
92. Mishra V, Jain NK (2014) Acetazolamide
u Y, Negi LM, Iqbal Z et al (2015)
Design and development of novel bioadhesive
niosomal formulation for the transcorneal
delivery of anti-infective agent: in-vitro and
ex-vivo investigations. Asian J Phar m Sci
10(4):322–330
(2023) Formulation and characterization of
epalrestat-loaded polysorbate 60 cationic niosomes for ocular delivery. Pharmaceutics
15(4):1247
Betaxolol-loaded niosomes integrated within
pH-sensitive in situ forming gel for management of glaucoma. Int J Pharm 598:120380
Latanoprost niosomes as a sustained release
ocular delivery system for the management
of glaucoma. Drug Dev Ind Pharm 46(5):
806–813
(2022) Recent developments of nanostructures for the ocular delivery of natural compounds. Front Chem 10:850757
Formulation and characterization of electrospun nanofibers for melatonin ocular delivery.
Pharmaceutics 15(4):1296
In-situ tear fluid dissolving nanofibers enable
prolonged viscosity-enhanced dual drug
delivery to the eye. Int J Pharm 616:121513
(2021) In vitro and in vivo biological assessment of dual drug-loaded coaxial nanofibers
for the treatment of corneal abrasion. Int J
Pharm 604:120732
tide nanofiber system for sustained delivery of
anti-vegf proteins to the eye vitreous. Pharmaceutics 15(4):1264
(2010) Designing dendrimers for ocular
drug deliver y. Eur J Med Chem 45(1):
326–334
encapsulated dendritic nanoarchitectures for
effective glaucoma management in rabbits.
Int J Pharm 461(1–2):380–390
93. Holden CA, Tyagi P, Thakur A et al (2012)
Polyamidoamine dendrimer hydrogel for
enhanced delivery of antiglaucoma drugs.
Nanomed Nanotechnol Biol Med 8(5):
776–783
94. Kambhampati SP, Bhutto IA, Wu T et al
(2021) Systemic dendrimer nanotherapies
for targeted suppression of choroidal inflammation and neovascularization
macular
527–540
95. Wang J, Li B, Huang D et al (2021) Nano-innano dendrimer gel particles for efficient topical delivery of antiglaucoma drugs into the
eye. Chem Eng J 425:130498
96. Coursey TG, Henriksson JT, Marcano DC
et al (2015) Dexamethasone nanowafer as an
effective therapy for dry eye disease. J Control
Release 213:168–174
97. Dourado LFN, da Silva CN, Gonc¸alves RS
et al (2022) Improvement of PnPP-19 peptide bioavailability for glaucoma therapy:
design and application of nanowafers based
on PVA. J Drug Deliv Sci Technol 74:103501
98. Emad Eldeeb A, Salah S, Ghorab M (2019)
Formulation and evaluation of cubosomes
drug delivery system for treatment of glaucoma: ex-vivo permeation and in-vivo pharmacodynamic study. J Drug Deliv Sci Technol
52:236–247
99. Gaballa SA, El Garhy OH, Moharram H et al
(2020) Preparation and evaluation of cubosomes/cubosomal gels for ocular delivery of
beclomethasone dipropionate for management of uveitis. Pharm Res 37(10):198
100. Abdelbary AA, Abd-Elsalam WH,
Al-Mahallawi AM (2016) Fabrication of
novel ultra deformable bilosomes for
enhanced ocular delivery of terconazole:
in vitro characterization, ex vivo permeation
and in vivo safety assessment. Int J Pharm
513(1–2):688–696
101. Abd-Elsalam WH, ElKasabgy NA (2019)
Mucoadhesive olaminosomes: a novel prolonged release nanocarrier of agomelatine for
the treatment of ocular hypertension. Int J
Pharm 560:235–245
102. Zuccari G, Carosio R, Fini A et al (2005)
Modified polyvinylalcohol for encapsulation
of all-trans-retinoic acid in polymeric micelles.
J Control Release 103(2):369–380
103. Peral A, Martinez-Aguila A, Pastrana C et al
(2020) Contact lenses as drug delivery system
for glaucoma: a review. Appl Sci 10(15):5151
104. Choi SW
lenses with polymeric vehicles for ocular drug
degeneration. J Control Release 335:
, Kim J (2018) Therapeutic contact
in age-related
282 Anuradha Nema
delivery
: a review. Materials (Basel) 11(7):
1125
105.
Maulvi F
review
lar drug
3017–
106. Jiao
contact
and
and
on
3026
Z,
Huo
tannic
cor
neal
A, Soni
TG,
therapeutic
delivery.
Q,
Lin X et
lens
based
for
acid
bacterial
repair. Carbohydr
Shah
contact
ug
Dr
al
(2022) Drug-free
on
quater
DO
lenses
Deliv
nized
keratitis
Polym
(2016)
for
23(8):
chitosan
therapy
ocu-
286:
119314
107. Ding X, Ben-Shlomo G, Que L (2020) Soft
contact lens with embedded microtubes for
sustained and self-adaptive drug delivery for
glaucoma treatment. ACS Appl Mater Interfaces 12(41):45789–45795
108. Cooper RC, Yang H (2019) Hydrogel-based
ocular drug delivery systems: emerging fabrication strategies, applications, and bench-tobedside manufacturing considerations. J
Control Release 306:29–39
109. Arranz-Romera A, Esteban-Perez S, GarciaHerranz D et al (2019) Combination therapy
and co-delivery strategies to optimize treatment of posterior segment neurodegenerative
diseases. Drug Discov Today 24(8):
1644–1653
110. Fang G, Wang Q, Yang X et al (2022)
γ-Cyclodextrin-based olypseudorotaxane
hydrogels for ophthalmic delivery of flurbiprofen to treat anterior uveitis. Carbohydr
Polym 277:118889
111. Gupta P, Yadav KS et al (2019) Applications
of microneedles in delivering drugs for various ocular diseases. Life Sci 237:116907
112. Shi H, Zhou J, Wang Y et al (2022) A rapid
corneal healing microneedle for efficient ocular drug delivery. Small 18(4):e2104657
113. Tawfk M, Chen F, Goldberg JL et al (2022)
Nanomedicine and drug delivery to the retina: current status and implications for gene
therapy. Naunyn Schmiedeberg’s Arch Pharmacol 395(12):1477–1507
114. Colella P, Cotugno G, Auricchio A (2009)
Ocular gene therapy: current progress and
future prospects. Trends Mol Med 15(1):
23–31
115. Kaemmerer WF (2018) How will the field of
gene therapy survive its success? Bioeng
Transl Med 3(2):166–177
116. Amador C, Shah R, Ghiam S et al (2022)
Gene therapy in the anterior eye segment.
Curr Gene Ther 22(2):104 –131
117. Ma Y, Lin H, Wang P et al (2023) A miRNAbased gene therapy nanodrug synergistically
enhances pro-inflammatory antitumor
immunity against melanoma. Acta Biomater
155:538–553
118. Kumar S, Fry LE, Wang JH et al (2023)
A
RNA-targeting strategies as a platform for
ocular gene therapy. Prog Retin Eye Res 92:
101110
119. Wang J, Zhao P, Chen Z et al (2023)
Non-viral gene therapy using RNA interference with PDGFR-α mediated epithelialmesenchymal transformation for proliferative
vitreoretinopathy. Mater Today Bio 20:
100632
120. Dhurandhar D, Sahoo NK, Mariappan I et al
(2021) Gene therapy in retinal diseases: a
review. Indian J Ophthalmol 69(9):
2257–2265
121. Kalluri R, LeBleu VS (2020) The biology,
function, and biomedical applications of exosomes. Science 367(6478):eaau6977
122. Dong X, Lei Y, Yu Z et al (2021) Exosomemediated delivery of an anti-angiogenic peptide inhibits pathological retinal angiogenesis.
Theranostics 11(11):5107–5126
123. Pifoux M, Silva AKA, Wilhelm C et al (2018)
Modification of extracellular vesicles by fusion
with liposomes for the design of personalized
biogenic drug delivery systems. ACS Nano
12(7):6830–6842
124. Pouton CW (2000) Lipid formulations for
oral administration of drugs:
non-emulsifying, self-emulsifying and “selfmicroemulsifying” drug delivery systems.
Eur J Pharm Sci 11(Suppl 2):S93–S98
125. Lopez-Cano JJ, Gonzalez-Cela-Casamayor
MA, Andre
´
s-Guerrero V et al (2022) Development of an osmoprotective microemulsion
as a therapeutic platform for ocular surface
protection. Int J Pharm 623:121948
126. Whitesides GM (2005) Nanoscience, nanotechnology, and chemistry. Small 1(2):
172–179
127. Ames P, Galor A (2015) Cyclosporine ophthalmic emulsions for the treatment of
dry eye: a review of the clinical evidence.
Clin Investig (Lond) 5(3):267–285
128. Mandal A, Gote V, Pal D et al (2019) Ocular
Pharmacokinetics of a topical ophthalmic
nanomicellar solution of cyclosporine
®
(Cequa
) for dry eye disease. Pharm Res
36(2):36
129. Kagkelaris K,
Panayiotakopoulos
kopoulos CD (2022) Nanotechnology-based
formulations to amplify intraocular bioavailability. Ther Adv Ophthalmol 14:
25158414221112356
130. U.S. National
Library of Medicine (2020)
POLAT-001 compared to latanoprost
G, Georga-
Ocular Drug Delivery: Overcoming Barriers for Effective Treatment 283
ophthalmic solution in patients with ocular
hypertension and open-angle glaucoma,
NCT02466399. https://classic.clinicaltrials.
gov. Accessed 20 April 2024
Chapter 13
Drug Delivery to the Gastrointestinal Tract: Challenges
and Opportunities
Milindmitra K. Lonare, Afroz Jahan, Manjinder Sharma,
and Sivaraman Ramanarayanan
Abstract
The effective oral drug delivery in animals and humans requires an understanding of their unique gastrointestinal tract (GIT) physiology and biochemical regulators. Oral drugs rely on how effectively absorbed
through the intestinal wall and come into systemic circulation. Absorption is hindered by various factors
within the enteric epithelium, such as efflux transporters, enzymatic degradation, tight junctions in addition
to intestinal linings, and first-pass hepatic metabolism. Factor related to the drugs are hydrophilicity or
lipophilicity, high molecular weight, or substrates of efflux transporters, another challenging limiting factor.
Thus, careful designing of oral delivery systems is required in order to improve the systemic availability of
drug by taking into various factors. The majority of drugs are taken orally, as this route is more convenient
and practical, except in emergency and hospitalized conditions. Despite advancements in the pharmaceutical industry, orally administered drugs many times fail to produce the desired effect due to limiting factors
of GIT. Here, we discussed the physiological and pharmacological aspects of the GIT. We also tried to
discuss the challenges underlying in oral drug delivery and future strategy for improvement of drug delivery
via the gastrointestinal tract.
Key words Drug deliver, Gastrointestinal-tract, First-pass metabolism, Efflux transporter, Metabolizing enzyme
1 Introduction
The gastrointestinal tract presents an appealing option for drug
administration because of its accessible entry point, extensive surface area for absorption, and efficient blood circulation that aids in
widespread distribution throughout the body. Furthermore, this
route is favored for its ease of use, cost-effectiveness (allowing
patients to self-administer, thus reducing therapy expenses), and
effective therapeutic outcomes. Consequently, these advantages
contribute to improved patient adherence to treatment
protocols [
1].
285
286 Milindmitra K. Lonare et al.
Despite its widespread use, drug delivery through the gastrointestinal tract remains challenging due to the complex anatomical
structure and physiological regulatory mechanisms. One significant
obstacle is the acidic environment of the stomach, which can
degrade or deactivate many drugs [
the presence of various digestive enzymes in the gastrointestinal
tract that can metabolize drugs before they are absorbed into the
bloodstream. Additionally, the permeability of the intestinal
mucosa can limit the absorption of certain drugs, particularly
those with large or hydrophilic molecules. Factors influencing this
include the disintegration and dissolution characteristics of drug
preparations, lipid solubility, particle size, and the drug’s pKa
[
3, 4].
Various factors such as disease conditions and surgical procedures affecting gastrointestinal anatomy and physiology can also
affect drug absorption through the GIT. To improve drug bioavailability, technologies such as nano carriers and permeation enhancers have been developed to enhance transport across the mucosal
barrier. Strategies to mitigate these challenges also include the use
of enzyme inhibitors or prodrugs that enhance drug activity and
reduce drug inactivation due to enzymatic metabolism in the GIT
. R
5]
ecent advancements in oral drug delivery systems have tack-
[
led challenges associated with anatomical barriers in the GIT, such
as the mucosal barrier that impedes drug absorption, along with
physiological factors like delayed absorption, taste concerns, gastric
irritation, first-pass metabolism, and the influence of the gastrointestinal environment on drug effectiveness [
Additionally,
ruminant species presents a significant challenge for the scientific
community. Ruminants such as cows, sheep, and goats have a
complex stomach structure consisting of four compartments: the
rumen, reticulum, omasum, and abomasum. This multi-chambered
system necessitates specialized drug delivery strategies to ensure
effective drug absorption during treatment. The rumen, which
houses a large microbial population, can metabolize drugs before
they reach absorption sites, thereby reducing bioavailability or
potentially disrupting normal microflora [
consider is the diet of ruminants, which can impact drug absorption. High-fiber diets may slow gastrointestinal transit time and
enhance drug absorption, whereas high-grain diets can expedite
passage through the GIT, reducing contact time with absorptive
surfaces [
bypass the rumen or release drugs at a controlled rate that aligns
with the animal’s digestive kinetics. Formulations needed for ruminants often provide protective coatings or encapsulation that prevent microbial drug degradation and premature drug release in the
rumen [
intact to the lower GI tract where absorption is more favorable.
2]. Another challenge involves
6].
drug delivery to the gastrointestinal tract (GIT) in
7].
Another factor to
8, 9]. Thus, targeted delivery systems are needed to
10].
These approaches aim to deliver the active ingredient
Drug Delivery to the Gastrointestinal Tract: Challenges and Opportunities 287
Therefore, targeted delivery systems are essential to bypass the
rumen or release dr ugs at a controlled rate that matches the digestive kinetics of the animal. Formulations designed for ruminants
often incorporate protective coatings or encapsulation to safeguard
against microbial drug degradation and premature release in the
rumen [
10]. These strategies aim to deliver the active ingredients
intact to the lower gastrointestinal tract where absorption is more
efficient.
2 Anatomy and Physiology of GIT
The gastrointestinal tract (GIT), or alimentary canal, is a fundamental component of the digestive system, comprising the mouth,
pharynx, esophagus, stomach, small intestine, and large intestine
1). It also includes accessory digestive organs such as the
(Fig.
salivary glands, liver, pancreas, and gallbladder. Functions of the
digestive system encompass ingestion, propulsion, mechanical and
chemical digestion, absorption, and defecation. Each organ plays a
critical role in breaking down food, releasing nutrients, and facilitating their absorption into the body [
segment exhibits unique anatomical, physiological, and biochemical characteristics that profoundly influence drug delivery, absorption, metabolism, and elimination.
11]. Importantly, each
Fig. 1 Illustration showing the gastrointestinal tract and different parts of the simple stomach
288 Milindmitra K. Lonare et al.
The alimentary canal is composed of four tissue layers, each
tailored to fulfill specific functions in different parts. These layers,
arranged from the lumen outward, include the mucosa, submucosa, muscularis, and serosa [
or mucous membrane, is responsible for mucus production. In
segments like the mouth, pharynx, esophagus, and anal canal, the
mucosa consists of non-keratinized, stratified squamous epithelium. In contrast, it comprises columnar epithelium in the stomach
and intestines. Goblet cells, which secrete mucus and fluid into the
lumen, and enteroendocrine cells, which release hormones into the
spaces between cells, are dispersed among the epithelial cells.
Intestinal epithelial cells play a crucial role in maintaining gut
balance by forming mucosal barriers that separate gut microbes
from the host immune system. These barriers encompass physical
defenses like the mucus layer and chemical defenses such as antimicrobial peptides (AMPs) produced by Paneth cells. Dysfunction of
these barriers can lead to intestinal inflammation, as observed in
conditions like inflammatory bowel diseases (IBD), characterized
by reduced mucus production and AMP levels. Moreover, intestinal
epithelial cells facilitate communication between gut microbes and
host immunity by generating cytokines, chemokines, and antimicrobial substances in response to environmental factors within the
gut. This interaction helps regulate immune responses and uphold
a symbiotic relationship between gut microbes and the host. The
critical role of gut epithelial cells in supporting immune function
and overall health is well recognized [
ing research aims to elucidate how epithelial cells precisely modulate immunity, produce antimicrobial peptides, and maintain gut
equilibrium.
The l
of loose connective tissue, blood vessels, and lymphatics that transport absorbed nutrients from the lumen to various parts of the
body. Additionally, the lamina propria serves as an immunomodulatory center, housing clusters of lymphocytes in the mucosaassociated lymphoid tissue (MALT). Particularly well-defined in
the ileum, these are known as “Peyer’s patches” and are distributed
throughout the small intestine, primarily on the antimesenteric
side. They include components such as high endothelial venules,
T cells, B cells, and follicular dendritic cells, organized into germinal centers, follicular areas, parafollicular areas, and dome areas,
each with distinct cellular compositions and functions [
The outer
mucosae, is a thin layer of smooth muscle that contributes to the
formation of folds in the mucosa, significantly increasing the surface area available for absorption. Directly beneath this layer, the
submucosa is histologically positioned and lies beneath the muscularis mucosae and muscularis layers. It comprises a broad array of
12]. The innermost layer, the mucosa
13, 14]. Nevertheless, ongo-
amina p
ropria, surrounding the epithelium, is composed
most layer of the mucosa, known as the muscularis
15]
.